Bone health is where the vitamin D story started

The discovery of vitamin D in the 1920s came directly from the search for what was causing rickets in children. A century later, bone health remains the most firmly established domain of vitamin D research, and also one of the most misunderstood. Most adults think a glass of fortified milk covers it. The reality is more complicated, and the stakes are higher than most people realize.

Osteoporosis affects an estimated 200 million people worldwide, and hip fractures carry a one-year mortality rate of 20 to 30 percent in older adults. Vitamin D alone does not prevent all of this, but it is one of the few modifiable variables with consistent mechanistic and clinical support.

How vitamin D supports bone: the mechanism

Vitamin D's central job in bone biology is enabling calcium absorption from the gut. Without adequate 25-hydroxyvitamin D (25(OH)D, the standard blood marker for vitamin D status), the intestine absorbs only about 10 to 15 percent of dietary calcium. With sufficient vitamin D, that rises to 30 to 40 percent. The active hormone form, 1,25-dihydroxyvitamin D (calcitriol), switches on calcium transport proteins in intestinal cells. Less calcitriol means less calcium reaches the bloodstream, which triggers parathyroid hormone (PTH) to pull calcium from bone to maintain serum levels. That constant borrowing from bone is what erodes density over years.

Vitamin D also directly influences osteoblasts (bone-building cells) and modulates the RANK-L pathway that controls osteoclast (bone-resorbing cell) activity. This dual action explains why the relationship between vitamin D status and bone mineral density shows up in both observational data and intervention trials. A detailed review of these pathways is available in Endocrine Reviews, which remains a foundational reference for clinicians and researchers.

What blood levels are actually needed for bone protection

The threshold question is where the clinical picture gets more specific. Levels below 20 ng/mL (below 50 nmol/L) are consistently associated with secondary hyperparathyroidism, elevated bone turnover markers, and reduced bone mineral density. Most guidelines define this as deficiency. Insufficiency falls between 20 and 29 ng/mL. A sufficient range is 30 to 60 ng/mL, and many endocrinologists and bone health specialists favor 40 to 60 ng/mL as a practical target for adults concerned about skeletal health.

A widely cited 2005 analysis in the American Journal of Clinical Nutrition found that PTH levels continued to fall as 25(OH)D rose up to approximately 30 to 40 ng/mL, suggesting that bone-protective effects increase across that range rather than plateauing at the arbitrary 20 ng/mL cutoff. Above 40 ng/mL, the marginal benefit appears to diminish for most skeletal outcomes.

Clinical trial evidence: supplements, fractures, and falls

The gold standard for any vitamin D claim is randomized controlled trial data, and bone health has more of it than almost any other vitamin D outcome. The picture from trials is more nuanced than early observational research suggested.

The vitamin D and calcium combination

The strongest fracture-reduction data comes from trials combining vitamin D with calcium. A landmark trial in French nursing home residents (Chapuy et al.) found that 800 IU/day of vitamin D3 plus 1,200 mg calcium reduced hip fracture risk by 43 percent over 18 months. The participants were severely deficient at baseline, which likely explains the large effect. That trial was published in The New England Journal of Medicine and is still referenced in current guidelines.

Vitamin D alone: a more complicated picture

When vitamin D is tested without calcium, fracture results are less consistent. A 2022 meta-analysis in The Lancet Diabetes & Endocrinology analyzed 11 trials and found no statistically significant reduction in hip or total fracture incidence from supplementation alone in generally healthy community-dwelling adults who were not severely deficient at baseline. This was widely misread as "vitamin D does nothing for bones," which oversimplifies the data. The populations studied were largely replete; putting already-adequate individuals into a trial and finding no added fracture benefit says nothing about correcting a genuine deficiency.

The VITAL trial, a large U.S. randomized trial of 2,000 IU/day of vitamin D3 in 25,871 participants, similarly found no significant reduction in fractures overall. Results were published in The New England Journal of Medicine. The median baseline level in VITAL was around 30 ng/mL, already at the sufficient threshold, which again limits what supplementation can add.

Fall prevention: a stronger signal

Fall prevention is where the vitamin D signal for bone-adjacent outcomes looks cleaner. Vitamin D supports muscle function through the same vitamin D receptors found in skeletal muscle, and adequate levels are associated with better grip strength, balance, and reaction time in older adults. A meta-analysis of 29 trials published in BMJ found that supplemental vitamin D (700 to 1,000 IU/day) reduced fall odds by 19 percent, particularly in those with low baseline levels. Fewer falls mean fewer fractures, especially in the hip.

Rickets and osteomalacia: the severe deficiency end

At the deficiency extreme, the skeletal consequences are unambiguous. Rickets in children (failure of growth plate mineralization, bowed legs, delayed closure of fontanelles) and osteomalacia in adults (diffuse bone pain, proximal muscle weakness, stress fractures) are both directly caused by inadequate vitamin D and resolve with repletion. These are not contested areas; the causal link is as well-established as any in nutritional medicine. What remains debated is how much benefit there is at the margins, correcting mild insufficiency in an otherwise healthy adult population.

Vitamin D, calcium, and vitamin K2: how they work together

A frequent omission in vitamin D and bone discussions is vitamin K2 (specifically MK-7). Vitamin D increases calcium absorption, but directing that calcium into bone rather than arterial walls requires carboxylation of osteocalcin and matrix Gla protein, both of which are K2-dependent. A 2013 randomized trial published in Osteoporosis International found that MK-7 supplementation significantly improved bone mineral density at the lumbar spine and femoral neck in postmenopausal women over three years. The practical implication for anyone supplementing vitamin D for bone health is that D3 combined with K2 (MK-7) is a more complete approach than D3 alone.

Magnesium is also worth noting. It is a cofactor in the enzymatic conversion of vitamin D to its active hormone form, and low magnesium blunts the response to supplementation. This partly explains why some trials show weak vitamin D effects: participants may be magnesium-insufficient, reducing activation efficiency regardless of the dose given.

Who is most at risk for bone loss from vitamin D deficiency

Several groups carry disproportionate risk. Older adults synthesize vitamin D in skin less efficiently (roughly 25 percent of the capacity of a 20-year-old), tend to spend less time outdoors, have lower dietary intake, and often have reduced kidney function, which impairs the final activation step. Postmenopausal women lose the protective effect of estrogen on osteoclast activity, making adequate vitamin D and calcium even more critical. People with darker skin tones require substantially more sun exposure for the same synthesis, a disparity that contributes to higher deficiency rates in populations who live at higher latitudes. Our article on vitamin D and skin tone covers the UVB-melanin relationship in detail.

People with malabsorption conditions (Crohn's disease, celiac disease, bariatric surgery) absorb less vitamin D from both diet and supplements, requiring higher doses and more frequent monitoring. Obese individuals sequester vitamin D in adipose tissue, which lowers circulating 25(OH)D for a given dose or sun exposure.

Sun versus supplements for bone: does the source matter

From a bone biology standpoint, what matters is the resulting 25(OH)D level in blood, regardless of whether it came from UVB-driven skin synthesis or an oral supplement. However, sun exposure has one practical advantage: the skin caps synthesis based on UVB dose, meaning sun alone does not cause vitamin D toxicity. Supplements, by contrast, can lead to toxicity (typically above 100 ng/mL) at very high doses sustained over time, though this requires taking well above recommended amounts for months. For the vast majority of people, sensible supplementation at 2,000 to 4,000 IU/day poses no toxicity risk and is a reliable way to maintain levels when sun is insufficient.

The deeper context on how these two pathways compare, including bioavailability differences and the unique advantages of each, is laid out in our guide on vitamin D from sun vs. supplements.

Practical supplementation guidance for bone health

For adults with confirmed deficiency (below 20 ng/mL) and bone health concerns, typical repletion doses range from 2,000 to 4,000 IU of vitamin D3 per day. Higher doses (up to 50,000 IU weekly for 8 to 12 weeks) are sometimes used medically to correct severe deficiency rapidly, but require monitoring. Maintenance doses of 1,000 to 2,000 IU/day are appropriate for adults with adequate baseline levels who want to hold them through winter or indoors-heavy periods.

Because vitamin D is fat-soluble, it is absorbed most efficiently when taken with the largest meal of the day. Testing 25(OH)D at least twice a year (at the end of summer and the end of winter) gives a clear picture of your actual range rather than a single snapshot. More on that process in our piece on vitamin D testing.

What about mega-doses and bone: the caution signal

One finding from trials that catches many people off guard: very high intermittent doses of vitamin D may actually increase fall and fracture risk in some older adults. A trial published in JAMA Internal Medicine found that monthly 60,000 IU doses increased falls in community-dwelling older adults compared to placebo. The proposed mechanism involves transient changes in calcium metabolism and possible downregulation of vitamin D receptors with bolus dosing. Daily moderate dosing, not large infrequent boluses, is the approach with the better safety record for bone outcomes.

Key Takeaways

Vitamin D deficiency (below 20 ng/mL) clearly harms bone by reducing calcium absorption, elevating PTH, and increasing bone resorption. Correcting it, especially in severely deficient populations, reduces fracture risk and fall risk with good clinical evidence behind both outcomes.

Trials in already-sufficient adults show little fracture benefit from supplementation, which is mechanistically logical, not a refutation of vitamin D's importance. The target zone for bone protection is roughly 30 to 60 ng/mL, with many specialists favoring 40 to 60 ng/mL as a practical optimal range.

D3 combined with K2 (MK-7), adequate calcium, and adequate magnesium is a more complete approach than vitamin D alone. Daily moderate dosing outperforms large intermittent boluses on both efficacy and safety grounds. And for most adults, achieving adequate levels requires a combination of whatever sun exposure is realistically available plus targeted supplementation across the months when UVB is insufficient.

What to do next

If you are not sure how much sun you actually need to maintain adequate levels at your latitude and skin tone, use the vitamin D sun exposure calculator to estimate your window for meaningful UVB. For ongoing tracking through seasons, Rays monitors your outdoor exposure automatically using your phone's location and UV data, so you know when you're falling short before the blood test tells you.